Preparing for 2026: 5 Priorities for Market Access Leaders

2026 isnโ€™t far off. Are your access priorities ready for the next wave of IRA-driven disruption? Between Inflation Reduction Act (IRA) implementation milestones, global pricing pressures, and payer adoption of new contracting models, the next 18 months will redefine...

MAVA in Action: Launch Strategy Shifted in Just 5 Days

Launch plans rarely survive first contact with payers. One immunology manufacturer learned this firsthand. Their internal strategy had a clear value story, aligned teams, and a rebate framework they believed would secure access. Then they tested it with MAVAยฎ. Launch...

MFN Deadline Is Here: How Pharma Teams Can Respond Strategically

๐—ฅ๐—ฒ๐—ด๐˜‚๐—น๐—ฎ๐˜๐—ผ๐—ฟ๐˜† ๐—”๐—น๐—ฒ๐—ฟ๐˜: ๐— ๐—™๐—ก ๐——๐—ฒ๐—ฎ๐—ฑ๐—น๐—ถ๐—ป๐—ฒ ๐—œ๐˜€ ๐—›๐—ฒ๐—ฟ๐—ฒ. ๐—œ๐˜€ ๐—ฌ๐—ผ๐˜‚๐—ฟ ๐—ง๐—ฒ๐—ฎ๐—บ ๐—ฅ๐—ฒ๐—ฎ๐—ฑ๐˜† ๐—ณ๐—ผ๐—ฟ ๐—ช๐—ต๐—ฎ๐˜ ๐—–๐—ผ๐—บ๐—ฒ๐˜€ ๐—ก๐—ฒ๐˜…๐˜? June 11 marks the end of the voluntary compliance window under the Most-Favored-Nation (MFN) Executive Order. If your organization hasnโ€™t finalized a pricing strategy, the time for...